Lars Jørgen Østergaard

Chlamydia pneumoniae and cardiovascular disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • The Department of Infectious Diseases
  • The Department of Medicine and Nephrology C
Chlamydia pneumoniae has been detected in atherosclerotic plaques, while seropositivity to this organism confers a slightly increased risk of coronary events. However, no aetiological link has been established; a major difficulty when investigating this link is the lack of a gold standard for diagnosing chronic vessel infection. The outcomes of case-control studies and prospective trials of macrolides in treatment and prevention of cardiovascular disease have been ambiguous but suggest a short-term preventive effect. Whether this is due to the antimicrobial or anti-inflammatory activity of the macrolides is unknown. Larger and longer prospective trials currently under way may provide better insight into the association of C. pneumoniae with cardiovascular disease. At present, there is no justification for treating cardiovascular disease with antibiotics.
Original languageEnglish
JournalMedical Journal of Australia
Pages (from-to)558-62
Number of pages4
Publication statusPublished - 2002

See relations at Aarhus University Citationformats

ID: 20341620